Universal patterns
Tracks universal DNA methylation patterns rather than patient-specific mutations
About mDETECTCutting-Edge
Cutting-Edge
Liquid Biopsy
Transforming Precision Oncology through early, actionable insights
Discover our story
From Research Bench to Clinical Impact
Our purpose
At mDETECT, we are advancing the future of cancer monitoring. By harnessing the power of epigenetics and circulating tumor DNA, our next-generation liquid biopsy platform is designed to provide oncologists with meaningful quantitative data on tumor burden. Our goal is to support timely clinical decisions in settings where every week counts.
Our Mission: To reduce uncertainty in cancer management by delivering accessible, rapid, and accurate liquid biopsy solutions intended to help inform care and improve patient outcomes.
The Challenge & Our Solution
The Challenge & Our Solution
The Gap in Current Cancer Monitoring
For patients undergoing treatment for solid tumors, relying solely on periodic imaging like CT or MRI scans can leave critical gaps between assessments, potentially delaying insights into whether a therapy is effective. Additionally, traditional blood-based assays targeting specific genetic mutations may face limitations when tumours evolve or exhibit high heterogeneity.
The mDETECT Epigenetic Advantage
The mDETECT tests analyze tumor-specific DNA methylation signatures, a type of epigenetic modification, that is present across widespread cancer types.
Our targeted Next-Generation Sequencing (NGS) assay measures subtle shifts in circulating tumor DNA from a simple, routine blood draw. This approach aims to support early evaluation of therapeutic response, providing clinicians with timely data to complement standard radiological imaging.
Filling gaps in your cancer care
The mDETECT Difference
2mL
Ultra-low sample requirements; 2mL of serum/plasma per patients is needed
Results in days
Rapid turnaround times with results in days
Clinical & Economic Impact
01Eliminates the need for custom test panels which are costly to the healthcare system
02Compact test design = lower cost, making frequent, longitudinal testing viable
03Empowers oncologists to stop ineffective treatment quickly and pivot to alternatives
Queen’s UniversityKingston, Ontario
Our beginnings
From Research Bench to Clinical Impact
Spun out from research at Queen’s University in Kingston, Ontario, mDETECT was founded to bridge the gap between epigenetic science and clinical care.
Backed by seed funding, competitive research grants, and clinical partnerships, our team is driving multi-center validation trials to bring methylation-based monitoring into routine cancer care worldwide.
Ready to collaborate? Whether you are a clinical researcher, biotech partner, or health system leader, reach out to learn how mDETECT is shaping the future of therapeutic monitoring.
Meet the Team
Contact us
Get in TouchPartner With Us
We are actively collaborating with clinical networks, diagnostic partners, and industry leaders to bring accessible precision monitoring to market.